BIOMAT Database Logo BIOMAT Database Logo

["Taurolin-Gel" and Taurolin-Trockengel" in treatment of osseous tissue inflammation]. 1990

S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
Kliniki Ortopedycznej AM w Warszawie.

The activity and principles of administration of Taurolin have been presented. That drug was used in 15 patients with chronic osteitis. Healing by first intention was obtained in 10 patients, necrosis of the skin occurred in 3 patients, recurrence of inflammation was found in one patient in whom accessory sequestroctomy was performed in the last case of osteitis and arteriosclerosis healing was obtained by second intention. The clinical observation of 15 patients has revealed: a) irritating influence of Taurolin on the soft tissue, b) increased phase of secretion of exudate since the 5 day after surgery, c) bactericidal influence of the drug. Sterilization of the focus occurred at 2 to 3 weeks after surgery. The use of Taurolin requires experience, complete abiding by the principles of use of this drug and equipment with a set of Charrier's drains. The authors are carrying on further observation of the use of Taurolin in the treatment of osteitis.

UI MeSH Term Description Entries
D010000 Osteitis Inflammation of the bone. Bone Inflammation,Inflammation, Bone
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005782 Gels Colloids with a solid continuous phase and liquid as the dispersed phase; gels may be unstable when, due to temperature or other cause, the solid phase liquefies; the resulting colloid is called a sol.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000891 Anti-Infective Agents, Local Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects. Anti-Infective Agents, Topical,Antiseptic,Antiseptics,Microbicides, Local,Microbicides, Topical,Antiinfective Agents, Local,Antiinfective Agents, Topical,Local Anti-Infective Agents,Local Antiinfective Agents,Topical Anti-Infective Agents,Topical Antiinfective Agents,Agents, Local Anti-Infective,Agents, Local Antiinfective,Agents, Topical Anti-Infective,Agents, Topical Antiinfective,Anti Infective Agents, Local,Anti Infective Agents, Topical,Local Anti Infective Agents,Local Microbicides,Topical Anti Infective Agents,Topical Microbicides
D013654 Taurine A conditionally essential nutrient, important during mammalian development. It is present in milk but is isolated mostly from ox bile and strongly conjugates bile acids. Taufon,Tauphon,Taurine Hydrochloride,Taurine Zinc Salt (2:1),Taurine, Monopotassium Salt
D013829 Thiadiazines
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
[Taurolin gel in treatment of osteitis (author's transl)].
June 1982, Aktuelle Traumatologie,
S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
[Treatment of post-traumatic osteomyelitis with Taurolin Gel].
January 1987, Magyar traumatologia, orthopaedia es helyreallito sebeszet,
S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
[Treatment of chronic osteomyelitis with Taurolin-Gel (author's transl)].
October 1981, Zeitschrift fur Orthopadie und ihre Grenzgebiete,
S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
[Local chemotherapy of osteitis with 4% taurolin-gel].
January 1983, Fortschritte der Medizin,
S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
[Treatment of local infection with taurolin].
January 1990, Aktuelle Probleme in Chirurgie und Orthopadie,
S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
AIDS and taurolin.
March 1986, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne,
S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
The treatment of peritonitis by an antiseptic - taurolin.
January 1981, Pharmatherapeutica,
S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
[Pharmacokinetics of Taurolin].
January 1982, Arzneimittel-Forschung,
S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
[Osseous intrauterine tissue].
September 1955, La Semana medica,
S Zawadziński, and G Benke, and S Eluszkiewicz, and A Wasikowski, and S Zarek
[Effect of Propolis-gel in the treatment of gingival inflammation].
January 1985, Stomatoloski vjesnik. Stomatological review,
Copied contents to your clipboard!